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The variation in individual responses to psychotropic drug treatment remains a critical problem in the management of psychotic
disorders. Although most patients will experience remission, some patients may develop drug-induced adverse eﬀects that may
range from troublesome to life threatening. Antidepressants are freely prescribed by general practitioners, and there should be
constant awareness in the medical community about possible serious side eﬀects. We describe two cases of adverse drug reactions
onlowdosage treatmentthat led toextreme psychoticepisodes as examples of thepotential fordangerous sideeﬀects. Thepatients
developed adverse reactions on the normal recommended dosage of nortriptyline, a tricyclics antidepressant (TCA). Both were
females,withnohistoryofantidepressanttreatment,unsocialbehaviour,noranyfamilyhistoryofpsychosis,butbothexperienced
severe psychiatric symptoms. Pharmacogenetic tests can easily be performed and interpreted according to the likelihood of adverse
reactions and should be included in toxicity interpretation.
1.Introduction
Two patients experienced single events of violent psychosis
after the tricyclic antidepressant nortriptyline was prescribed
in low dosages. Both patients were female, one Caucasian
and the other Asian. Both were drug na¨ ıve with no history
of any prescription or illicit drug use prior to the initiation
of treatment. Both patients had neither history of antisocial
behaviour nor any family history of psychosis.
Patient A. Female, 40 years old, Caucasian, with no history
of violent behaviour or psychotic disorders in her family.
She suﬀered from stress-induced mood changes. Her doctor
recognised depression and prescribed nortriptyline, 10mg
4times/day. According to her husband, the next day she
started to behave abnormally, complaining that she was
hearing strange voices. On the third day, she experienced a
sever psychotic episode. As the patient herself described, she
felt dizzy, disorientated and was suﬀering from delusions.
Since withdrawal of the drug, she has not experienced
another episode. Pharmacogenetic tests revealed a loss-of-
function CYP2D6∗4/∗41 polymorphism.
Patient B. Female, 17 years old, Asian, with no history
of violent behaviour or psychotic disorders in her family.
She suﬀered from stress during her high school exams.
Depression was recognised by her doctor and nortripty-
line was prescribed, 10mg 3times/day. After two weeks,
she was admitted to the hospital with a severe psychotic
episode. Since withdrawal of the drug, she has not expe-
rienced another episode. Pharmacogenetic tests revealed a
CYP2D6∗10/∗10 polymorphism with diminished enzyme
activity.
Epidemiological studies suggest that depression is the
second most signiﬁcant cause of disability in the health care
arena. Up to 10% of the population at any one point in
time may be depressed and up to 45% of the population
may, at some point during their lifetime, suﬀer from a
depressive episode [1]. The prescription of antidepressants
has increased rapidly in recent years.2 ISRN Pharmaceutics
Tricyclic antidepressants (TCAs) are an older class of
medication used for mood disorders and major depression.
Themechanismofactionisthroughblockingoftheneuronal
uptake of norepinephrine, serotonin, and dopamine. Anti-
cholinergic, adrenergic and alpha-blocking actions of TCAs
contributetovarioussideeﬀects. TCAs have a very lipophilic
nature and exhibit signiﬁcant binding to proteins. This can
be problematic in a case of overdose because both forced
diuresis and hemodialysis are not helpful in eliminating the
drug from the system [2].
TCAs are high-clearance drugs that are metabolised via
multiple pathways involving both phase I (P450) and phase
II (glucuronidation) processes. Elimination is dependent
on hepatic hydroxylation via the cytochrome P450 mixed-
function oxidase system, especially CYP2D6 [3–6], and con-
jugation with glucuronic acid [7].
Drugs which are the substrates for CYP2D6 are known
to interfere with TCA metabolism [8–11], conﬁrming the
importance of CYP2D6 in nortriptyline metabolism. A
signiﬁcant correlation between amitriptyline clearance and
the debrisoquine metabolic ratio has been observed in non-
smokers [4], supporting some CYP2D6 dependence.
Tricyclic antidepressants have a moderate therapeutic
index,astheyproducesigniﬁcantadverseeﬀectsattherapeu-
tic concentrations and are dangerous in overdose. Signiﬁcant
side eﬀects of TCAs are common and their prevalence is
estimated as high as 5%, while acute poisoning with TCAs
is potentially life threatening [12]. Central nervous system
manifestations of toxicity include agitation, stupor, coma,
seizure, and manic excitement. The plasma level correlates
poorly with the severity of symptoms, and peak blood
levels over 1000ng/mL have a higher risk of cardiac and
CNS toxicity [13, 14]. TCAs exist as tertiary or secondary
amines and the tertiary forms are metabolised to secondary
amines. Both tertiary and secondary amines are active, as
are some of the subsequent hydroxylated metabolites. The
tertiary amines are metabolised by many P450s, whereas
the secondary amines are largely metabolised by CYP2D6
(Figure 1).
The major metabolite produced by CYP2D6, E-10-hy-
droxynortriptyline, has approximately half the potency of
the parent drug in inhibiting noradrenaline reuptake and
greatly reduced anticholinergic activity. It is often present at
comparable (or higher) concentrations to the parent drug
and may contribute to the antidepressant eﬀects [15].
1.1. Genetic Polymorphisms. It is now recognised that genetic
polymorphism diﬀerences in the metabolism of drugs can
have a great inﬂuence on the eﬃcacy and toxicity of
medications. People with a particular genotype, or genetic
characteristic, may suﬀer adverse responses to particular
drugs, and such responses may be traced through families,
ethnic groups, and geographic clusters. All pharmacogenetic
polymorphisms, or relatively stable variations of the genes
involved in drug metabolism, have been found to diﬀer in
frequency among some ethnic and racial groups.
Cytochrome P450 2D6 is responsible for the metabolism
of approximately 25% of prescription medicine. Many
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Figure 1: Nortriptyline metabolism.
of these drugs are antipsychotic or antidepressant drugs,
making it an important metabolic enzyme for psychiatry.
Racial and ethnic studies of drug metabolism have shown
substantial interpopulation diﬀerences in CYP2D6 enzyme
activity. The activity of the CYP2D6 enzyme is extremely
variable, due to the more than 50 recognised genetic varia-
tions, and it can be described as having four main levels of
activity (http://www.cypalleles.ki.se/). The most important
phenotype is the loss-of-function polymorphism or in some
nomenclatures “poor metaboliser” (PM). The prevalence of
loss-of-function polymorphisms in diﬀerent ethnic groups
has been extensively studied. In Caucasian populations, the
prevalence of PMs is 5–10% [16–19]; in Asians—about 1%
[20–24] and 0–19% in the African population [21–23, 25].
The prevalence of ultraextensive metabolisers is reported
with a prevalence of 1.5–29% in diﬀerent ethnic groups [26].
TheethnicvariabilityinCYP2D6activitycanbeattribut-
ed to genetic polymorphism of the CYP2D6 gene as a result
of multiple mechanisms, including single point mutation,
insertions or deletions, complete gene deletions, and gene
duplication and multiplication. The major genetic polymor-
phisms associated with the poor metabolism phenotype lead
to the complete lack of a functional protein.
The most common allele associated with poor metabo-
lism is CYP2D6∗4 which accounts for more than 70% of
CYP2D6 alleles in loss-of-function polymorphism subjects
[27] .G o u g he ta l .[ 28] identiﬁed a G-to-A transition at the
ﬁrst nucleotide of exon 4 in the CYP2D6 gene, resulting in
a shift of the splice site and introduction of a premature
termination codon. The mutant protein had no residual
activity. In DNA from an individual who was deﬁcient in
debrisoquine metabolism, Hanioka et al. [29] identiﬁed a
1934G-A transition (CYP2D6∗4) at the junction of the third
intron and fourth exon, resulting in an aberrant 3-prime
splice recognition site and an mRNA with a single basepair
deletion. The disrupted mRNA leads to a truncated protein
withoutfunctionalactivity.TheyshowedthattheCYP2D6∗4
homozygote or heterozygote state produces nonfunctional
proteins, which is the cause of poor drug metabolism.
CYP2D6 1934G>A (also seen as 1846G>A in the literature)
is diagnostic for the nonfunctional CYP2D6∗4h a p l o t y p e
[30]. This variant is responsible for the majority of loss-
of-function polymorphisms found in Caucasian populations
[31] and is also found at much lower frequencies in other
populations, such as Koreans [32].
CYP2D6 100C>T (also seen as 188C>T in the literature)
is part of both the nonfunctional CYP2D6∗4h a p l o t y p e
and the reduced function CYP2D6∗10 haplotype. According
to Gaedigk et al. [33], the presence of CYP2D6 100C>TISRN Pharmaceutics 3
(188C>T) is diagnostic of CYP2D6∗10. In vitro studies in
both COS-1 [34] and V79 [35] cells have shown that cells
transfected with CYP2D6 100C>T alone exhibit reduced
function, suggesting that this mutation contributes to the
reduced function of the CYP2D6∗10 allele. Some attempts
have been made to ﬁnd an association of this polymorphism
withgeneralisedtonicclonicseizures,asseeninepilepsy[36]
and tardive dyskinesia, in Chinese schizophrenic patients
[37].
1.2. Dysfunctional CY2D6 Alleles and TCA Metabolism. In
1998 Dal´ en et al. [38] reported 3.3-, 2.8-, and 0.7-fold
diﬀerences in the mean nortriptyline clearance between
the groups of diﬀerent CYP2D6 genotypes in Caucasians.
Changes in clearance have also been seen with reduced
activity alleles, including CYP2D6∗10, in Asian subjects [39,
40].
Steimer et al. [41] demonstrated that dysfunctional
CYP2D6alleleshadagreaterriskofsideeﬀectswithamitrip-
tyline, 150mg daily, than those with two functional alleles
(77% versus 12%), and this risk was associated with higher
nortriptyline concentrations.
Dizziness and sedation have been described with ele-
vated nortriptyline concentrations in patients with a loss-
of-function CYP2D6 genotype and individuals receiving
CYP2D6 inhibitors [42, 43]. It was also shown that patients
with ultrahigh activity of CYP2D6 showed treatment resis-
tance [44].
Clinical manifestation of neurotoxicity is very complex
and not clearly deﬁned. Furthermore, all factors should be
included in the evaluation of toxicity. It is not a surprise
that clinical symptoms, like salivation, accommodation,
sedation,bloodpressure,andpulseratedidnotvarybetween
genotypes in a single-dose study in healthy subjects nor of
patients with depression [38]. Also some results suggested
that CYP2D6 polymorphisms did not inﬂuence the rate
of adverse reactions to nortriptyline; however, with only
10 poor metabolisers (and the involvement of two drugs),
the study was underpowered to detect moderate or small
diﬀerences [45].
As the main nortriptyline metabolite is active, altered
parent/metabolite ratios may be the reason that altered
eﬀects have been diﬃcult to demonstrate; that is, there is
minimal change in overall molar activity. It is notable that
the major metabolite does not seem to have been measured
in most of the assessments and is not considered clinically
during therapeutic drug monitoring.
2. Method
Blood samples were referred to our laboratory by clinical
doctors. Genotyping for CYP2D6 has been described in our
previous publication in Pharmacogenomics [46].
3. Results
Patient A genotyping results revealed Cytochrome P450
polymorphism CYP2D6∗4/∗41.
Patient B genotyping results revealed Cytochrome P450
polymorphism CYP2D6∗10/∗10.
4. Discussion
Many factors can inﬂuence the eﬃcacies and adverse reac-
tions of medications, including age, gender, organ function
(in particular the liver and kidneys), drug interactions,
the nature and severity of the disease intended to treat,
and the presence of other diseases. Nevertheless, genetic
polymorphisms and gender account for the main variability
in drug metabolism.
4.1. Cytochrome P450 Genetic Polymorphisms. Molecular
genetics provides a practical approach to identifying bio-
logical predictors of psychotropic drug responses and drug-
induced adverse events. A medication that is safe and
eﬀective in one patient may be ineﬀective or even harmful in
another. The identiﬁcation of relevant gene polymorphisms
in patients prior to drug prescription will allow physicians
to customise the selection of medication to meet individual
patient needs.
As described earlier, several pharmacogenetic studies
have focused on polymorphisms in liver cytochrome P450
isoenzymes which metabolise many antidepressant medica-
tions. The most intensively investigated gene is CYP2D6 and
the CYP2D6 genotype has been shown to predict tricyclics
concentrations in blood.
The Caucasian patient described in this publication, who
had a CYP2D6∗4/∗41 polymorphism with loss-of-function
enzyme activity, exhibited her psychotic episode on the
third day after treatment initiation. In contrast, the Asian
patient with CYP2D6∗10∗10 polymorphism, with partially
decreased enzyme activity, developed neurotoxicity syn-
drometwoweeksaftertreatmentinitiation.Thisisconsistent
withcurrentpharmacogenetic knowledge ofCYP2D6 loss-of
function polymorphisms.
4.2.GenderDiﬀerencesinResponsetoAntidepressant. Gender
diﬀerences in the diagnosis and treatment of mental disor-
ders are described in numerous publications.
It was shown that women appeared to have diﬀerent
plasma concentrations of antidepressants during treatment
than men [47–50].
Yue et al. [40] pointed out, for example, that the monthly
alterations in hormones in women may act on dopamine
receptorsinaprotectivemanner,muchlikeneuroleptics,and
women require lower doses of psychotropics. McEwan [51]
showed that antidepressants and neuroleptics have diﬀering
actions in men and women because of the eﬀects of estrogen
and testosterone in the brain.
Furthermore, medications act diﬀerently in women
before and after menopause and some researches suggest the
eﬀects of the menstrual cycle on pharmacokinetics [52–55].
It is also known that adipose tissue and body ﬂuid
quantities aﬀect drug dosage and rate of metabolism and
should be considered in the prescription of drug treatments.4 ISRN Pharmaceutics
Pregnancy and menopause also aﬀect the concentration of
plasma proteins, and thus of protein-bound drugs [56].
Overall, women may experience more side eﬀects or
toxicity from the same dosage of a drug than do men.
5. Conclusion
Drug toxicology evidence is currently based on the drug to
metabolite ratio in blood or urine. However, measurement
of metabolites and their contribution to the validation of
neurotoxicity remains uncertain due to the methodology
of detection and lack of scientiﬁcally based evidence. In
addition, each person is unique in his/her susceptibility to
toxic agents.
Interactionsbetweensubstancesmetabolisedthroughthe
Phase I cytochrome P450 system and an individual’s varia-
tion in enzyme activity should be included in the assessment
of toxicity. The described patient cases are illustrations of
the value of individual interpretation of diminished Phase 1
metabolism and its consequences.
There are often severe eﬀects arising from the toxicity of
antipsychoticmedication.However,pharmacogenetictesting
willhelptoavoidadversereactionsbyprovidinginformation
about an individual’s drug metabolising capacity, thereby
identifying the patients for whom a drug would be safe and
eﬀective. Phase 1 cytochrome P450 loss-of-function poly-
morphisms should be included in patient record warning
labels, similar to allergies, as a warning that an individual
patient is susceptible to particular adverse drug reactions.
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